Drugs / GEO-D02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04041674 | Mar → Sep 2022 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEO-D02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04041674 ↗ |
| Modality | Vaccine | “prime-boost vaccine regimen of GEO-D02 DNA and MVA/HIV62B” NCT04041674 ↗ |
| Route | Intramuscular | “GEO-D02 DNA by intramuscular (IM) injection” NCT04041674 ↗ |